<DOC>
	<DOCNO>NCT02665065</DOCNO>
	<brief_summary>The primary objective study demonstrate efficacy Iomab-B , conjunction Reduced Intensity Conditioning ( RIC ) regimen protocol-specified allogeneic hematopoietic stem cell transplant ( HCT ) , versus Conventional Care .</brief_summary>
	<brief_title>Study Iomab-B Prior HCT v . Conventional Care Older Subjects With Active , Relapsed Refractory AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Have active , relapsed refractory Acute Myeloid Leukemia ( AML ) . Active , relapse refractory AML define either ( 1 ) primary induction failure ( PIF ) 2 cycle chemotherapy , ( 2 first early relapse remission duration few 6 month , ( 3 ) relapse refractory salvage combination chemotherapy contain highdose AraC , ( 4 ) second subsequent relapse Have document CD45 expression leukemic cell via flow cytometry ( `` blast gate '' CD45 vs. side scatter analysis consistent AML ) Be least 55 year age Have circulate blast count le 10,000/mm3 ( control hydroxyurea allow ) Have calculate creatinine clearance ( CockroftGault equation ) &gt; 50 mL/min Have adequate hepatic function ( bilirubin , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , define ≤ 2 time upper limit normal [ ULN ] ) Have Karnofsky score ≥ 70 Have expect survival &gt; 60 day Have central venous catheter line place prior study treatment administration Have 8/8 allelelevel , relate unrelated , HSC donor match human leukocyte antigen ( HLA ) A , HLAB , HLAC , DRB1 For woman childbearing potential , surgically sterile agree practice abstinence utilize acceptable contraception ( intrauterine , injectable , transdermal , combination oral contraceptive ) 1year post transplant ; For male sexually active woman childbearing potential must surgically sterile use acceptable method contraception ( define barrier method conjunction spermicide ) time screen 12 week last dose study drug Be able understand study procedure , agree participate study program , voluntarily provide write Informed Consent Have circulate HAMA note initial screening Have receive prior radiation , ( maximally tolerate level ) , normal organ Have active leukemic central nervous system ( CNS ) involvement , define leukemic blast detect CSF morphology flow cytometry and/or chloromas detect CNS image Have previously receive HCT Have clinically significant cardiac disease ( NYHA Class III IV ) ; clinically significant arrhythmia i.e . ventricular tachycardia , ventricular fibrillation , `` Torsade de Pointes '' . Myocardial infarction uncontrolled angina within 6 month , congestive heart failure , clinical significant cardiomyopathy Have abnormal QTcF ( &gt; 450milliseconds ) electrolyte correct ( least two different ECG reading least 15 minute reading ) Have know prior positive test result human immunodeficiency virus ( HIV ) hepatitis B ( HBV ) C. Subjects positive HBV test result due previously vaccinate hepatitis B , evidence negative hepatitis B surface antigen ( HBsAg ) , negative anti hepatitis B core protein ( HBc ) positive antibody HBsAg ( antiHBs ) exclude Have active serious infection uncontrolled antibiotic antifungal Have acute promyelocytic leukemia associate cytogenic translocation : ( 15/17 ) Have active malignancy within 2 year entry . Exceptions exclusion include : treated nonmelanoma skin cancer , carcinoma situ cervical intraepithelial neoplasia , successfully treat organconfined prostate cancer evidence progressive disease base prostate specific antigen ( PSA ) level active therapy Have receive biologic therapy within 3 week</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Leukemia , Acute Myeloid</keyword>
	<keyword>Myeloid Leukemia , Acute</keyword>
	<keyword>Bone Marrow Cell Transplantation</keyword>
	<keyword>Transplantation , Bone Marrow</keyword>
	<keyword>HCT</keyword>
	<keyword>HSCT</keyword>
	<keyword>Refractory AML</keyword>
	<keyword>Relapsed AML</keyword>
	<keyword>BC8</keyword>
	<keyword>I-131</keyword>
	<keyword>Iomab</keyword>
	<keyword>Iomab-B</keyword>
	<keyword>CD45</keyword>
	<keyword>Iodine</keyword>
	<keyword>Iodine-131</keyword>
	<keyword>131-I</keyword>
	<keyword>AML</keyword>
	<keyword>BMT</keyword>
	<keyword>radioimmunotherapy</keyword>
</DOC>